Behavioral Clinical Research — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$1,091,509	9
2024	Research	$1,150	4
2022	Research	$76,632	22
2021	Research	$63,929	3
2019	Research	$8,012	1

Breakdown

Who paid Research payments · program years 2019–2025

E.R. Squibb & Sons, L.L.C. $961,615 5 payments
AbbVie, Inc. $131,044 8 payments
Jazz Pharmaceuticals Inc. $76,632 22 payments
Merck Sharp & Dohme Corporation $63,929 3 payments
H. Lundbeck A S $8,012 1 payment

Studies the money was for Research payments · program years 2019–2025

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $891,358 1 payment
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (10 mg and 30 mg QD) of CVL-231(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $129,894 4 payments
A Multicenter Phase 2 12-Week Double-Blind Placebo-Controlled Randomized Parallel-Group Study of Jzp150 for the Treatment of Posttraumatic Stress Disorder $76,632 22 payments
A Phase 2a, Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-1942 Added to Stable Antidepressant Therapy in Participants With Treatment-Resistant Depression $63,929 3 payments
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder $36,247 1 payment
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) $29,156 1 payment
Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia DayBreak $8,012 1 payment
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder $3,395 1 payment
A Phase 3, Open-label Extension Study to Assess the Long-term Safety of KarXT for the Treatment of Mania or Mania with Mixed Features in Bipolar-I Disorder $1,460 1 payment
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Two Fixed Doses (15 mg and 30 mg QD) of?CVL-231?(Emraclidine) in Participants With Schizophrenia Experiencing an Acute Exacerbation of Psychosis $1,000 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.